By Dr. Simon Bates, Rigaku Americas Corp X-ray powder diffraction has been the gold standard for solid state pharmaceutical analysis for quite some time. However, when it comes to...
Dr. Simon Bates is currently V.P. of Science and Technology at Rigaku Americas Corp., where he nurtures collaborative relationships between industry partners and academia in the discovery of new...
Dr. Robert Docherty did his degree and PhD. at Strathclyde University and joined ICI/Zeneca in 1988 where he worked on the solid-state structure and crystallization of dyes, pigments, biocides,...
By Dr. Bob Docherty, Pfizer The focus would be on solid form screen & selection, crystallization process development, pre-formulation evaluations, particle engineering and projecting the API attributes to drug...
Dr. Ahmad Sheikh, Head of Solid State & Comp.Chem., AbbVie Ahmad Sheikh is Senior Research Fellow and Head of Solid-State Chemistry at AbbVie. He has over 20 years...
By Dr. Ahmad Sheikh, AbbVie While new chemical entities represent majority of the drugs approved in the last five years, the diversity and complexity of these molecules continue...
By Dr. Jeremy M. Merritt, Eli Lilly and Co. Abstract: pending
Dr. Jeremy M. Merritt is a Director at Eli Lilly and Co. in the small molecule design and development organization (SMDD). He currently leads the Particle Design Lab (PDL)...
